Panacea Biotec Secures $8.2M UNICEF Oral Polio Vaccine Award

NEW DELHI — Indian biotechnology and pharmaceutical manufacturer Panacea Biotec Limited announced on Wednesday, August 5, 2026, that it has received a new Letter of Award from the United Nations International Children's Emergency Fund (UNICEF) valued at approximately $8.205 million (around ₹78.24 crore). The award covers the supply of bivalent Oral Polio Vaccine (bOPV) during calendar year 2028.

The latest procurement order forms part of an ongoing multi-year Long-Term Agreement between Panacea Biotec and UNICEF. Under the agreement, which runs from April 1, 2026, to March 31, 2030, the company supplies critical immunization doses to support global polio eradication programs. Official disclosures outlining the terms of the transaction were formally submitted to domestic regulatory authorities at BSE Limited and the National Stock Exchange of India (NSE).

Panacea Biotec Secures Key International Supply Agreement

The newly awarded contract expands Panacea Biotec's international supply commitments to global public health organizations. The award specifically covers the production and delivery of bOPV formulation in both 10-dose and 20-dose vial presentations.

According to regulatory filings submitted under SEBI listing regulations, the primary details of the transaction include:

• Contract Value: Approximately $8.205 million (~₹78.24 crore).

• Procurement Entity: United Nations International Children's Emergency Fund (UNICEF).

• Execution Timeline: Calendar Year 2028.

• Product Specification: Bivalent Oral Polio Vaccine (bOPV) delivered in 10-dose and 20-dose presentations.

• Agreement Framework: Order issued pursuant to the existing Long-Term Agreement covering April 2026 through March 2030.

Long-Term Framework and Global Eradication Strategy

The award follows an earlier corporate disclosure dated October 3, 2025, when Panacea Biotec first announced its multi-year Long-Term Agreement with UNICEF. That initial arrangement secured bOPV supply commitments across the second quarter of CY2026 and the full CY2027 period. The August 4, 2026 Letter of Award officially extends operational visibility into calendar year 2028.

Oral polio vaccines remain a fundamental tool for international health agencies working to prevent wild and variant poliovirus transmission in endemic and high-risk regions. Panacea Biotec operates as a key supplier in global immunization initiatives, maintaining specialized manufacturing facilities certified under international regulatory standards.

Regulatory Compliance and Ownership Structure

The corporate submission signed by Ankit Jain, General Manager - Legal & Company Secretary, confirmed that the contract involves no related-party transactions. Neither the promoters nor promoter group companies maintain any financial or ownership interest in the awarding agency, UNICEF.

The regulatory disclosure was completed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Official Sources Section

Details regarding the supply award were published in official corporate filings submitted by Panacea Biotec Limited to market regulators. Regulatory documentation and financial disclosures are archived on the official portals of BSE Limited and the National Stock Exchange of India (NSE).

Quote Section

According to official company filings submitted to domestic stock exchanges on August 5, 2026:

"In terms of the aforesaid Long-Term Agreement, the Company has received Letter of Award for supply of bOPV in 10 and 20 dose presentation worth ~US$ 8.205 million (~Rs.78.24 Crore) in Calendar Year 2028."

Why It Matters

The award reinforces supply chain predictability for global public health campaigns working toward complete polio eradication. For global health organizations like UNICEF, long-term procurement frameworks ensure steady availability of affordable, high-quality vaccines in vulnerable regions. For investors and market analysts, the $8.205 million order enhances long-term revenue visibility for Panacea Biotec through 2028 within its core biologicals manufacturing division.

Key Facts at a Glance

• Total Order Value: ~$8.205 million (approximately ₹78.24 crore).

• Awarding Agency: UNICEF (International procurement).

• Product: Bivalent Oral Polio Vaccine (bOPV) in 10 and 20-dose presentations.

• Execution Period: Calendar Year 2028.

• Parent Agreement: Part of 2026–2030 UNICEF Long-Term Agreement framework.

Frequently Asked Questions (FAQ)

Q1: What is the total value of the UNICEF order awarded to Panacea Biotec?

The Letter of Award is valued at approximately $8.205 million, which translates to around ₹78.24 crore.

Q2: What product will Panacea Biotec supply under this contract?

Panacea Biotec will supply bivalent Oral Polio Vaccines (bOPV) packaged in 10-dose and 20-dose vial presentations.

Q3: When will the vaccines be delivered?

The contract specifies delivery during calendar year 2028.

Q4: How does this order fit into Panacea Biotec's existing agreements?

The order is part of a broader Long-Term Agreement signed with UNICEF that spans from April 1, 2026, to March 31, 2030.

Source: Panacea Biotec Limited, National Stock Exchange of India (NSE), BSE Limited